skip to Main Content

Circulating Tumor DNA as a Potential Marker of Adjuvant Chemotherapy Benefit Following Surgery for Localized Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
In early-stage pancreatic cancer there are no currently no biomarkers to guide selection of therapeutic options. This prospective biomarker trial evaluated the feasibility and potential clinical utility of circulating tumour DNA (ctDNA) analysis to inform adjuvant therapy decision making.

Read more . . . 

Back To Top